Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) and Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends.
Valuation & Earnings
This table compares Vivos Therapeutics and Enliven Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vivos Therapeutics | $17.44 million | 0.69 | -$21.17 million | ($2.14) | -0.40 |
| Enliven Therapeutics | N/A | N/A | -$103.69 million | ($1.67) | -20.78 |
Profitability
This table compares Vivos Therapeutics and Enliven Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vivos Therapeutics | -127.70% | -2,325.64% | -98.12% |
| Enliven Therapeutics | N/A | -21.04% | -20.41% |
Analyst Recommendations
This is a breakdown of recent recommendations for Vivos Therapeutics and Enliven Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vivos Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
| Enliven Therapeutics | 1 | 0 | 4 | 1 | 2.83 |
Vivos Therapeutics presently has a consensus target price of $2.80, suggesting a potential upside of 223.89%. Enliven Therapeutics has a consensus target price of $61.80, suggesting a potential upside of 78.05%. Given Vivos Therapeutics’ higher possible upside, equities research analysts plainly believe Vivos Therapeutics is more favorable than Enliven Therapeutics.
Insider & Institutional Ownership
26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by company insiders. Comparatively, 3.0% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Risk & Volatility
Vivos Therapeutics has a beta of 6.1, meaning that its share price is 510% more volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500.
Summary
Enliven Therapeutics beats Vivos Therapeutics on 9 of the 14 factors compared between the two stocks.
About Vivos Therapeutics
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
About Enliven Therapeutics
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
